Literature DB >> 21173911

Hepatocellular carcinoma, with portal thrombus after viral eradication, disappeared by 5-fluorouracil and interferon.

Tomofumi Miura1, Nobuaki Suzuki, Junichiro Nakamura, Satoshi Yamada, Tsutomu Miura, Masahiko Yanagi, Hiroyuki Usuda, Iwao Emura, Toru Takahashi.   

Abstract

Hepatocarcinogenesis after a sustained virological response (SVR) in type C chronic hepatitis and cirrhosis is an important issue in endemic areas; hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) therapy is especially very hard. We herein report a first case in which combination therapy with interferon-α and continuous intra-arterial infusion of 5-fluorouracil (designated as FAIT) provided a complete response in HCC with PVTT after SVR. Therefore, we think that FAIT is a good option to treat HCC with or without PVTT, even after SVR.

Entities:  

Keywords:  5-Fluorouracil intra-arterial infusion; Hepatocellular carcinoma; Portal vein tumor thrombus; Sustained virological response

Year:  2010        PMID： 21173911      PMCID： PMC3004036          DOI： 10.4254/wjh.v2.i11.416

Source DB:  PubMed          Journal:  World J Hepatol


  18 in total

1.  Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.

Authors:  Masato Sakon; Hiroaki Nagano; Keizo Dono; Shoji Nakamori; Koji Umeshita; Akira Yamada; Sumio Kawata; Yasuharu Imai; Shohei Iijima; Morito Monden
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

2.  Expression of interferon alpha/beta receptor in human hepatocellular carcinoma.

Authors:  M Kondo; H Nagano; M Sakon; H Yamamoto; O Morimoto; I Arai; A Miyamoto; H Eguchi; K Dono; S Nakamori; K Umeshita; K Wakasa; Y Ohmoto; M Monden
Journal:  Int J Oncol       Date:  2000-07       Impact factor: 5.650

3.  Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.

Authors:  Miharu Hirakawa; Kenji Ikeda; Yasuji Arase; Yusuke Kawamura; Hiromi Yatsuji; Tetsuya Hosaka; Hitomi Sezaki; Norio Akuta; Masahiro Kobayashi; Satoshi Saitoh; Fumitaka Suzuki; Yoshiyuki Suzuki; Hiromitsu Kumada
Journal:  Intern Med       Date:  2008-10-01       Impact factor: 1.271

4.  Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.

Authors:  Hiroaki Nagano; Atsushi Miyamoto; Hiroshi Wada; Hideo Ota; Shigeru Marubashi; Yutaka Takeda; Keizo Dono; Koji Umeshita; Masato Sakon; Morito Monden
Journal:  Cancer       Date:  2007-12-01       Impact factor: 6.860

5.  Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy.

Authors:  Tameyoshi Yamamoto; Hiroaki Nagano; Yasuharu Imai; Kazuto Fukuda; Hitoshi Matsumoto; Motoi Kondo; Hideo Ota; Masato Nakamura; Hiroshi Wada; Takehiro Noda; Bazarragchaa Damdinsuren; Keizo Dono; Koji Umeshita; Shoji Nakamori; Masato Sakon; Kenichi Wakasa; Morito Monden
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402

6.  Combination therapy with 5-fluorouracil and IFN-alpha2a induces a nonrandom increase in DNA fragments of less than 3 megabases in HT29 colon carcinoma cells.

Authors:  R W Horowitz; B G Heerdt; X Hu; E L Schwartz; S Wadler
Journal:  Clin Cancer Res       Date:  1997-08       Impact factor: 12.531

7.  Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

Authors:  S Nishiguchi; T Kuroki; S Nakatani; H Morimoto; T Takeda; S Nakajima; S Shiomi; S Seki; K Kobayashi; S Otani
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321

8.  Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection.

Authors:  Hiroshi Wada; Hiroaki Nagano; Takehiro Noda; Bazarragchaa Damdinsuren; Shigeru Marubashi; Atsushi Miyamoto; Yutaka Takeda; Koji Umeshita; Keizo Dono; Masato Sakon; Kenichi Wakasa; Morito Monden
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 6.772

9.  Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.

Authors:  T Noda; H Nagano; I Takemasa; S Yoshioka; M Murakami; H Wada; S Kobayashi; S Marubashi; Y Takeda; K Dono; K Umeshita; N Matsuura; K Matsubara; Y Doki; M Mori; M Monden
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

10.  Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.

Authors:  H Ota; H Nagano; M Sakon; H Eguchi; M Kondo; T Yamamoto; M Nakamura; B Damdinsuren; H Wada; S Marubashi; A Miyamoto; K Dono; K Umeshita; S Nakamori; K Wakasa; M Monden
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640
View more
  2 in total

1.  Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.

Authors:  Abeer A Bahnassy; Abdel-Rahman N Zekri; Ahmed El-Bastawisy; Amal Fawzy; Marwa Shetta; Nehal Hussein; Dalia Omran; Abdallah A S Ahmed; Samir S El-Labbody
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

2.  Surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus: a novel classification.

Authors:  Jiang-feng Xu; Xi-yu Liu; Shuai Wang; Huai-xi Wen
Journal:  World J Surg Oncol       Date:  2015-02-28       Impact factor: 2.754
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.